Targeted Immunotherapy for Breast Cancer Immunotherapy- Fact, myths and experience: Mythbusters: How beautiful facts can falsify ugly Theories

Joint Event on Cancer Treatment & Breast Cancer and Biomarkers

March 20-21, 2019 Paris, France

Charles Wiseman

Briacell Therapeutics, USA

Keynote: J Cancer Sci Ther

Abstract :

In the 70â??s, there was great excitment about the promise of BCG to as an new approach to treating many cancers, breast cancer included. That idea didnâ??t prove true, as did many widely held concepts. We have come a long way in the past 50 years, and it should be helpful to pay some attention to the developments that led us to the current state. The recent positive results with the SV-BR1-GM targeted therapy stand in contrast to some of the previous â??widely held conceptsâ??; During the discussion, I will discuss objective findings that refute the following: Breast cancer is not immunogenic Targeted Immunotherapy is effective only if <10^6 cells BCG can aid tumor regression and extend survival Chemotherapy is immunosuppressive and would neutralize any immunotherapybenefit The brain is a privileged site, Responses to immunotherapy are very slow Considering some of the past perspectives, with my discussion of the positive results of my own work and that of others, I will offer a few speculations and discuss some unsolved challenges to developing an effective therapy for breast cancer.

Biography :

Charles Wiseman is Clinical Professor of Medicine at the Division of Medical Oncology, Keck-USC School of Medicine, and previously was Acting Chief of the Division of Oncology/Hematology at White Memorial Medical Center. Dr. Wiseman has been cited in US News Top Doctors yearly since 2002. He brings more than 40 years of academic and clinical experience to BriaCell Therapeutics Corp. As Co-Founder of BriaCell, he is the inventor for most of the Company’s intellectual property and actively participates in its ongoing technology development. As the former Director of the Breast Cancer Basic Research Laboratory at the University of Texas M.D. Anderson Hospital in the 1970s, he was one of the pioneers of the field of cancer vaccine therapeutics. He has written in over 100 peer-reviewed publications and medical textbook chapters.

E-mail: cw@briacell.com